A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken January in 2021.
13:33 JST, May 11, 2022
A total of 5 million doses of a novel coronavirus vaccine developed by U.S. biopharmaceutical firm Novavax Inc. are ready to be supplied nationwide by July, according to the health ministry.
The Health, Labor and Welfare Ministry plans to deliver Novavax vaccines to medical institutions according to the number of requests.
According to the ministry, 1 million doses of vaccine is expected to be available from late May to mid-June, followed by 2 million doses each in late June and late July.
The Novavax vaccine is targeted at ages 18 and older and will be used in the first through third rounds of inoculation.
The ministry has requested that each prefecture establish at least one vaccination location, and stated that it will not set an upper limit on the number of vaccination sites per prefecture due to the increasing supply.
Novavax vaccines, which can be stored in an ordinary refrigerator at 2 C to 8 C, are considered easy to handle at medical institutions.
In Japan, Takeda Pharmaceutical Company Limited, which received the technology transfer from Novavax, manufactures the product.
"Society" POPULAR ARTICLE
-
M4.9 Earthquake Hits Tokyo, Neighboring Prefectures
-
M7.5 Earthquake Hits Northern Japan; Tsunami Waves Observed in Hokkaido, Aomori and Iwate Prefectures
-
Fire Damages 170 Buildings in Oita, Western Japan
-
Beloved Cat Stationmaster Nitama in Wakayama Pref. Passes Away at 15
-
M5.7 Earthquake Hits Japan’s Kumamoto Pref., Measuring Upper 5 Intensity, No Tsunami Expected
JN ACCESS RANKING
-
Japan’s Hopes for Seafood Exports Shot Down in China Spat
-
Essential Services Shortage to Hit Japan’s GDP By Up to ¥76 Tril. By 2040
-
Japan to Charge Foreigners More for Residence Permits, Looking to Align with Western Countries
-
Japan Exports Rise in October as Slump in U.S. Sales Eases
-
Niigata Gov. to OK Restart of N-Plant; Kashiwazaki-Kariwa May Be Tepco’s 1st Restarted Plant Since 2011

